Improving business and operations planning
How does a non-integrated S&OP approach affect you?
A company that does not have its regulatory function integrated with its S&OP process can face issues.
Global life sciences companies face different regulatory compliance issues in every country in which they conduct business.
A company that does not have its regulatory function integrated with its S&OP process can face quality and shipment holds while the compliance issues are addressed. Shipment delays not only affect financial results, but can also cause risks to patient health.
Under the new HITECH provisions, the sanctions for non-compliance are substantial. They include new tiered fines with a potential maximum of $1.5 million per identical violation per year.
To understand the current state of your company’s S&OP process, ask the following questions:
- When was the last time we examined our S&OP process?
- Do all stakeholders have a seat at the table? Do stakeholders understand their responsibilities so that they can be held accountable?
- When was the S&OP process mapped out and assessed against long-term strategy?
- How will our long-term strategy for emerging markets impact our supply chain?
- Will we have enough capacity to meet the requirements and opportunities of new markets?
- How much complexity are we adding into our existing business?
- Has our outsourcing strategy impacted our capabilities to supply customers and be flexible?
<< Previous | Next >>
Answers to your questions, at a glance
- Arvin Goldberg
+1 703 747 1429
- Bradley Newman
Partner — Americas Advisory
Supply Chain & Operations
+1 312 879 4083